Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineBempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Bempedoic acid is currently approved for two patient subgroups. This 3-year, double-blind, randomized, placebo-controlled trial examined cholesterol-lowering and CV protective effects in a broader population of approximately 14,000 patients with elevated cholesterol who were unable or unwilling to take statins. The drug was 21% more effective than placebo at reducing LDL in this trial. There was a small but significant reduction in primary events of CV-related death, MI, stroke, or coronary revascularization.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form